SynaptogenixSNPX
Market Cap: $4.42M
About: Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Employees: 5
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
4.1% less ownership
Funds ownership: 4.42% [Q1] → 0.32% (-4.1%) [Q2]
64% less funds holding
Funds holding: 22 [Q1] → 8 (-14) [Q2]
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
90% less capital invested
Capital invested by funds: $168K [Q1] → $16.2K (-$152K) [Q2]
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 15
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Jason McCarthy 31% 1-year accuracy 5 / 16 met price target | 329%upside $14 | Buy Upgraded | 11 Jul 2024 |